finance and restructuring operations
Thierry Hercend, M.D., Ph.D. , has over 30 years of experience in both academia and the pharmaceutical industry, in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Thierry Hercend has held the position of Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Thierry Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe at Vertex Pharmaceuticals. Dr. Hercend joined the pharmaceutical industry in 1990 as director of the immunology therapeutic area and then scientific director of the healthcare division at Roussel - Uclaf. Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Hemato - Immunology Unit of the Gustave Roussy Cancer Institute, Villejuif, France, Director of Inserm Unit U333 with a focus on tumor immunology and Professor of Immunology at the Medical Faculty of Paris XI University. Thierry Hercend has authored more than 120 publications in oncology, autoimmune diseases and transplantation.
oncology, autoimmune diseases and transplantation.